179898-27-2 Usage
Uses
Used in Pharmaceutical Industry:
(3-AMINO-2-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of various organic compounds for the development of pharmaceutical products. Its unique structure and reactivity make it a valuable component in creating new drugs and therapeutic agents.
Used in Agrochemical Production:
In the agrochemical industry, (3-AMINO-2-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is utilized in the production of various agrochemicals, contributing to the development of effective solutions for agricultural applications, such as pesticides and herbicides.
Used in Organic Synthesis:
(3-AMINO-2-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the preparation of diverse types of biologically active molecules in the field of organic synthesis. Its specific chemical properties allow for the creation of a wide range of compounds with potential applications in various industries.
Used as a Reagent in Chemical Reactions:
Due to its specific chemical properties, (3-AMINO-2-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is employed as a reagent in various chemical reactions, facilitating the synthesis of complex organic compounds and contributing to advancements in chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 179898-27-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,8,9 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 179898-27:
(8*1)+(7*7)+(6*9)+(5*8)+(4*9)+(3*8)+(2*2)+(1*7)=222
222 % 10 = 2
So 179898-27-2 is a valid CAS Registry Number.
179898-27-2Relevant articles and documents
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines
Hamann, Lawrence G.,Higuchi, Robert I.,Zhi, Lin,Edwards, James P.,Wang, Xiao-Ning,Marschke, Keith B.,Kong, James W.,Farmer, Luc J.,Jones, Todd K.
, p. 623 - 639 (2007/10/03)
A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR- mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure - activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.
